Bio Joo1, Mi-Suk Park2, Soo Hyeon Lee3, Hye Jin Choi4, Seung Tack Lim4, Sun Young Rha4, Itay Rachmilevitch5, Young Han Lee1, Jin-Suck Suh1. 1. Department of Diagnostic Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 2. Department of Diagnostic Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. radpms@yuhs.ac. 3. Pfizer Oncology, Seoul, Korea. 4. Institute of Oncology, Yonsei University College of Medicine, Seoul, Korea. 5. InSightec, Haifa, Israel.
Abstract
PURPOSE: We evaluated the safety and effectiveness of the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate Conformal Bone System for the palliation of painful bone metastases. MATERIALS AND METHODS: Our Institutional Review Board approved this study, and all patients gave informed consent prior to enrollment. A total of six painful metastatic bone lesions in five patients were treated using MRgFUS with the ExAblate Conformal Bone System for pain palliation. The follow-up sessions were at 3 days, 2 weeks, 1, 2, and 3 months, and 1 year after treatment. Efficacy was evaluated by the changes in visual analog scale (VAS) scores. At 3-months and 1-year follow-ups, unenhanced computed tomography and contrast-enhanced MR imaging examinations were performed. All adverse events were assessed to evaluate treatment safety. RESULTS: All patients showed significant pain relief within 2 weeks. Two patients experienced complete pain reduction that lasted for 1 year. Two other patients showed pain relief measured as VAS scores of 2 and 4 on their last follow-up. Although the remaining patient had experienced significant pain relief in two lesions, the VAS score re-increased on his last follow-up. The size of the enhancing soft tissue mass in metastatic lesions decreased, and new bone formation was seen on follow-up images. Although adverse events were not serious, non-specific leg pain and second degree skin burn were noted. CONCLUSION: MRgFUS was demonstrated to be effective palliative treatment within 2 weeks in selected patients with painful bone metastases.
PURPOSE: We evaluated the safety and effectiveness of the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate Conformal Bone System for the palliation of painful bone metastases. MATERIALS AND METHODS: Our Institutional Review Board approved this study, and all patients gave informed consent prior to enrollment. A total of six painful metastatic bone lesions in five patients were treated using MRgFUS with the ExAblate Conformal Bone System for pain palliation. The follow-up sessions were at 3 days, 2 weeks, 1, 2, and 3 months, and 1 year after treatment. Efficacy was evaluated by the changes in visual analog scale (VAS) scores. At 3-months and 1-year follow-ups, unenhanced computed tomography and contrast-enhanced MR imaging examinations were performed. All adverse events were assessed to evaluate treatment safety. RESULTS: All patients showed significant pain relief within 2 weeks. Two patients experienced complete pain reduction that lasted for 1 year. Two other patients showed pain relief measured as VAS scores of 2 and 4 on their last follow-up. Although the remaining patient had experienced significant pain relief in two lesions, the VAS score re-increased on his last follow-up. The size of the enhancing soft tissue mass in metastatic lesions decreased, and new bone formation was seen on follow-up images. Although adverse events were not serious, non-specific leg pain and second degree skin burn were noted. CONCLUSION: MRgFUS was demonstrated to be effective palliative treatment within 2 weeks in selected patients with painful bone metastases.
Entities:
Keywords:
Magnetic Resonance-guided Focused Ultrasound; bone metastases; high-intensity focused ultrasound; pain palliation
Authors: Elizabeth A Stewart; Wladyslaw M W Gedroyc; Clare M C Tempany; Bradley J Quade; Yael Inbar; Tilman Ehrenstein; Asher Shushan; Jonathan T Hindley; Robert D Goldin; Matthias David; Miri Sklair; Jaron Rabinovici Journal: Am J Obstet Gynecol Date: 2003-07 Impact factor: 8.661
Authors: Matthew P Goetz; Matthew R Callstrom; J William Charboneau; Michael A Farrell; Timothy P Maus; Timothy J Welch; Gilbert Y Wong; Jeff A Sloan; Paul J Novotny; Ivy A Petersen; Robert A Beres; Daniele Regge; Rodolfo Capanna; Mark B Saker; Dietrich H W Grönemeyer; Athour Gevargez; Kamran Ahrar; Michael A Choti; Thierry J de Baere; Joseph Rubin Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Michael Chan; Kristopher Dennis; Yuexi Huang; Charles Mougenot; Edward Chow; Carlo DeAngelis; Jennifer Coccagna; Arjun Sahgal; Kullervo Hynynen; Gregory Czarnota; William Chu Journal: Technol Cancer Res Treat Date: 2016-08-01
Authors: Lazzaro di Biase; Emma Falato; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Flavia Narducci; Vincenzo Di Lazzaro Journal: Neurol Res Int Date: 2021-06-29
Authors: Joe D Baal; William C Chen; Ulysis Baal; Sagar Wagle; Jed H Baal; Thomas M Link; Matthew D Bucknor Journal: Skeletal Radiol Date: 2021-05-21 Impact factor: 2.199